WO2007058359A1 - グレリン及びその誘導体又はGHS-R1aに作用する物質を有効成分とする皮膚修復促進治療剤 - Google Patents
グレリン及びその誘導体又はGHS-R1aに作用する物質を有効成分とする皮膚修復促進治療剤 Download PDFInfo
- Publication number
- WO2007058359A1 WO2007058359A1 PCT/JP2006/323226 JP2006323226W WO2007058359A1 WO 2007058359 A1 WO2007058359 A1 WO 2007058359A1 JP 2006323226 W JP2006323226 W JP 2006323226W WO 2007058359 A1 WO2007058359 A1 WO 2007058359A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- residue
- acid sequence
- amino
- peptide
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 95
- 239000004480 active ingredient Substances 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 20
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 17
- 101800001586 Ghrelin Proteins 0.000 title description 11
- 102000012004 Ghrelin Human genes 0.000 title 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 48
- 230000001737 promoting effect Effects 0.000 claims abstract description 40
- 239000000122 growth hormone Substances 0.000 claims abstract description 24
- 102000018997 Growth Hormone Human genes 0.000 claims abstract description 23
- 108010051696 Growth Hormone Proteins 0.000 claims abstract description 23
- 230000028327 secretion Effects 0.000 claims abstract description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 103
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 95
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 89
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 65
- 210000004927 skin cell Anatomy 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 59
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 45
- 239000000194 fatty acid Substances 0.000 claims description 45
- 229930195729 fatty acid Natural products 0.000 claims description 45
- 150000004665 fatty acids Chemical class 0.000 claims description 45
- 150000001413 amino acids Chemical class 0.000 claims description 43
- 210000003491 skin Anatomy 0.000 claims description 39
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 230000037380 skin damage Effects 0.000 claims description 19
- 230000036560 skin regeneration Effects 0.000 claims description 19
- 102000000393 Ghrelin Receptors Human genes 0.000 claims description 16
- 108010016122 Ghrelin Receptors Proteins 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 208000028990 Skin injury Diseases 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 44
- 235000001014 amino acid Nutrition 0.000 description 26
- 230000001605 fetal effect Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 22
- 230000009471 action Effects 0.000 description 14
- 238000002054 transplantation Methods 0.000 description 14
- -1 NN161) Chemical compound 0.000 description 11
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 description 11
- 230000008439 repair process Effects 0.000 description 11
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 238000012258 culturing Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- UMUPQWIGCOZEOY-JOCHJYFZSA-N 2-amino-2-methyl-n-[(2r)-1-(1-methylsulfonylspiro[2h-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)N1CCC2(C3=CC=CC=C3N(C2)S(C)(=O)=O)CC1)OCC1=CC=CC=C1 UMUPQWIGCOZEOY-JOCHJYFZSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 231100000019 skin ulcer Toxicity 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NEHWBYHLYZGBNO-BVEPWEIPSA-N (2s)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[(2-amino-2-methylpropanoyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)C(C)(N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 NEHWBYHLYZGBNO-BVEPWEIPSA-N 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000007256 Nevus Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 108010027047 ipamorelin Proteins 0.000 description 3
- 229950002987 ipamorelin Drugs 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000013076 target substance Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- SBJLJOFPWOYATP-XMMPIXPASA-N 3-amino-3-methyl-n-[(3r)-2-oxo-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-4,5-dihydro-3h-1-benzazepin-3-yl]butanamide Chemical compound C([C@H](C1=O)NC(=O)CC(C)(N)C)CC2=CC=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 SBJLJOFPWOYATP-XMMPIXPASA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 206010011985 Decubitus ulcer Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WURGZWOTGMLDJP-ZCYANPAGSA-N (e)-5-amino-n,5-dimethyl-n-[(2r)-1-[methyl-[(2r)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound C([C@H](C(=O)NC)N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)C1=CC=CC=C1 WURGZWOTGMLDJP-ZCYANPAGSA-N 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical group CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241001504505 Troglodytes troglodytes Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 108010051768 des-n-octanoyl ghrelin Proteins 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003273 male-pattern hair loss Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ACYBVNYNIZTUIL-UHFFFAOYSA-N n'-benzylethane-1,2-diamine Chemical compound NCCNCC1=CC=CC=C1 ACYBVNYNIZTUIL-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 125000005474 octanoate group Chemical group 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000006128 skin development Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229950008131 tabimorelin Drugs 0.000 description 1
- 108010064878 tabimorelin Proteins 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
Definitions
- the present invention relates to a skin cell proliferation action of a substance that acts on a growth hormone secretagogue receptor (GHS-R). More specifically, the present invention relates to a skin injury therapeutic agent, a skin regeneration promoting agent, a skin cell culture method and the like in the treatment of skin injury containing the substance as an active ingredient.
- GHS-R growth hormone secretagogue receptor
- Skin is the earliest tissue for which transplantation treatment has been attempted, even before the long history of skin transplantation. Furthermore, when looking at future transplantation regeneration research, it is considered that the organization that has been fully verified for access access and generation / regeneration processes through skin development research and hair regeneration research. Moreover, skin transplant regeneration research is a research area that can be directly applied to various skin diseases such as burns, congenital epidermolysis bullosa, Yes! /, And male pattern hair loss, and is important for skin damage or skin injury. Is expected to play an important role (Non-Patent Document 1).
- the required skin for the cultured skin differs depending on the disease, the degree of injury, the transplant area, and the like. Transplantation of only the cultured epidermis is appropriate for moderate burns, etc., and patients with full-thickness skin need cultured skin that incorporates the dermis layer. In addition, for the treatment of intractable skin ulcers in diabetic patients and the like, it is desired to develop wound-covered cultured skin that is expected to release physiologically active substances (Non-patent Document 2).
- cultured skin sheets used for skin transplantation include normal epidermal keratinocytes (Non-Patent Document 3) by a method developed by Green et al. And skin equivalent tissue devised by Bell et al. (Non-Patent Document 4).
- Green et al. Succeeded in obtaining sufficient proliferation by suppressing the differentiation of epidermal keratinocytes by using 3T3 cells as supporting cells.
- epidermal keratinocytes in the culture are stratified, so they have a sheet-like structure, and cultured cell structures similar to living organisms have proven clinically useful as an alternative to skin tissue.
- Non-patent Document 5 Previously prepared a portion corresponding to the dermis using a material such as collagen, and cultured epidermal keratinocytes thereon. In this method, it is important to use a material for incorporating cells three-dimensionally to construct an artificial tissue, and collagen gel was a material suitable for this (Non-patent Document 5).
- Non-patent Document 6 a substance that promotes cell proliferation and differentiation.
- Some clinical applications such as IGF, TGF- ⁇ , and FGF are also wary of causing abnormalities in the cell division of other parts of the human body. Discovery of highly safe substances with such activity * Development is desired.
- Ghrelin is a hormone whose gastric strength was also discovered in 1999. It has an amino acid sequence consisting of 28 residues, and the third amino acid from the N-terminus of the sequence is glycated with a fatty acid. It is a peptide having an extremely unusual chemical structure (Non-patent Document 8, Patent Document 1). Ghrelin acts as a growth hormone secretagogue receptor la (GHS-Rla) (Non-patent document 9), and promotes endogenous brain digestion that enhances the secretion of growth hormone (GH) from the pituitary gland.
- GGS-Rla growth hormone secretagogue receptor la
- Non-Patent Document 8 It has been shown to be a tubal hormone (Non-Patent Document 8), and recent studies have shown that darrelin increases appetite, increases body weight and fat by subcutaneous administration, and improves cardiac function It has also been clarified that it has actions such as (Non-Patent Documents 10 to 14).
- darrelin has a GH secretion-promoting action and an appetite-enhancing action, an effect of burning fat through the action of GH and converting it into energy, or an effect of enhancing the muscles by expressing the anabolic action of GH. It is expected that can be extracted more effectively by increasing appetite (Non-patent Document 15).
- Darrelin is an endogenous GHS for GHS—Rla, and was isolated and purified from rats for the first time, followed by vertebrates other than rats, such as humans, mice, pigs, chickens, unagi, ushi, horses, The amino acid of darrelin with a similar primary structure from Hedge, L (IZ ⁇ storm 2 solid) Hd) n3 ⁇ 4VcI (iMS33 ⁇ 43 ⁇ 4H & A3 ⁇ 4HH3cISld (0UBinq-u) sSD:
- the peptide is a peptide having a specific structure in which the side chain hydroxyl group of the serine residue (S) or threonine residue (T) at the 3-position is acylated with a fatty acid such as octoate or decanoate. No bioactive peptide having such a hydrophobic modification structure has been isolated from living organisms other than darelin.
- GHS-Rla growth hormone releasing peptide 2
- GHRP-2 growth hormone releasing peptide 2
- GHRP-6 His- D- Trp- Ala- Trp- D- Phe- Lys- N
- L-692,429 MK-0751
- L-163,191 MK-0677
- ipamorelin ipamorelin, NN161
- tabimorelin tabmorelin, NN703
- CP-424,391 CP-424,391
- GHS-Rla is expressed in skin cells, and substances acting on GHS-Rla, including ghrelin, act on skin cells to show the proliferation effect of skin cells. No reports have been found yet.
- Patent document 1 International publication 01Z07475 pamphlet
- Non-Patent Document 1 Kyoto University 21st Century COE Program HP “Formation of an international center for fusion transplantation regeneration treatment” Research on skin transplantation regeneration, http: ⁇ www.kuhp.kyoto-u.ac.jp ⁇ coe / memberl5. html
- Non-Patent Document 2 Takamura: Bio Venture, 1: 58 (2001)
- Non-Patent Document 3 Rheinwald and Green: Cell, 6: 331 (1975)
- Non-Patent Document 4 Bell et al: Science, 211: 1052 (1981)
- Non-Patent Document 5 Tsuji: Special Issue on Experimental Medicine, 19: 2121 (2001)
- Non-Patent Document 6 Ueda: Bio Venture, 1: 32 (2001)
- Non-Patent Document 7 Hohfeld et al .: Lancet, 366: 788-790 (2005)
- Non-Patent Document 8 Kojima et al .: Nature, 402, 656-660 (1999)
- Non-Patent Document 9 Howard et al: Science 273: 974-977 (1996)
- Non-Patent Document 10 Wren et al .: Endocrinology 141: 4325-4328 (2000)
- Non Patent Literature l l Nakazato et al .: Nature 409: 194-198 (2001)
- Non-Patent Document 12 Shintani et al: Diabetes 50: 227-232 (2001)
- Non-Patent Document 13 Lely et al .: Endocr. Rev. 25: 426-457 (2004)
- Non-patent literature 14 Korbonits et al .: Front Neuroendocrino. 25: 27-68 (2004)
- Non-patent literature 15 Red water, Samukawa: Latest medicine, 60: 1569-1573 (2005)
- the present invention relates to providing a skin damage therapeutic agent, a skin regeneration promoting agent, a skin cell culturing method, and the like in the treatment of skin damage using a substance having a skin cell proliferating action.
- the present inventors promote the growth of the fetus when a substance acting on GHS-Rla is administered to a pregnant mother, and the administered substance moves to the fetus and also to the amniotic fluid. I found out. Considering the function and role of substances that act on GHS-Rla in amniotic fluid, it was expected to show a proliferative effect on fetal skin cells.
- the present inventors examined the action of a substance that acts on GHS-Rla on fetal skin cells. As a result, the presence of GHS-Rla in skin cells and the substance that acts on GHS-Rla It has been found that it acts on skin cells to promote intracellular calcium production, and that the substance exhibits a proliferation effect of skin cells.
- the present invention relates to a skin regeneration promoter in the treatment of skin damage comprising a substance acting on GHS-Rla as an active ingredient, a promoter for forming a cultured skin cell sheet by culturing skin cells, and transplantation of cultured skin.
- the present invention relates to an agent for promoting skin repair and treatment.
- the present invention also provides a method for treating skin damage comprising administering a substance that acts on GHS-Rla, a method for promoting the formation of a cultured skin cell sheet by culturing skin cells, and at the time of transplanting cultured skin.
- the present invention relates to a method for promoting skin repair and a method for treating the above-mentioned diseases by promoting the repair.
- the present invention relates to a skin regeneration accelerator in the treatment of skin damage, a formation promoter of a cultured skin cell sheet by culturing skin cells, and promotion of skin repair during transplantation of cultured skin.
- a skin injury therapeutic agent comprising as an active ingredient a substance that acts on a growth hormone secretagogue receptor or a pharmaceutically acceptable salt thereof.
- the substance has the amino acid sequence shown in SEQ ID NO: 1, and the third amino acid residue from the amino terminal is a modified amino acid residue in which a fatty acid is introduced into the side chain of the amino acid residue A peptide, and an amino acid sequence described in SEQ ID NO: 1 having an amino acid sequence in which one to several amino acids are deleted, substituted, and Z or appended in the amino acid sequence from the amino acid terminus to the fifth to 28th amino acids,
- the third amino acid residue is a peptide selected from the group consisting of peptides which are modified amino acid residues in which a fatty acid is introduced into the side chain of the amino acid residue, or a pharmaceutically acceptable salt thereof (above) 1)
- the therapeutic agent described described.
- a modified amino acid residue in which the substance has the amino acid sequence set forth in SEQ ID NO: 1 and a serine residue located at the third position of the amino terminal force is a fatty acid introduced into the hydroxyl group of the side chain of the residue.
- the substance is a peptide having the amino acid sequence shown in SEQ ID NO: 1, wherein the side chain hydroxyl group of the serine residue located third from the amino terminal is acylated with an n-otatanyl group.
- a skin regeneration promoter comprising as an active ingredient a substance that acts on a growth hormone secretion promoting factor receptor or a pharmaceutically acceptable salt thereof.
- the substance has the amino acid sequence of SEQ ID NO: 1, and the third amino acid residue from the amino terminal is a modified amino acid residue in which a fatty acid is introduced into the side chain of the amino acid residue A peptide, and an amino acid sequence described in SEQ ID NO: 1 having an amino acid sequence in which one to several amino acids are deleted, substituted, and Z or appended in the amino acid sequence from the amino acid terminus to the fifth to 28th amino acids,
- the third amino acid residue is a peptide selected from the group consisting of peptides which are modified amino acid residues in which a fatty acid is introduced into the side chain of the amino acid residue, or a pharmaceutically acceptable salt thereof (above) 6)
- the accelerator as described.
- a modified amino acid residue in which the substance has the amino acid sequence set forth in SEQ ID NO: 1, and a serine residue located at the third position of the amino terminal force is a fatty acid introduced into the hydroxyl group of the side chain of the residue.
- the above substance is a peptide having the amino acid sequence shown in SEQ ID NO: 1, wherein the side chain hydroxyl group of the serine residue located third from the amino terminal is acylated with an n-otatanyl group.
- the amino acid sequence of SEQ ID NO: 1 has an amino acid sequence in which one to several amino acids are deleted, substituted and Z or appended in the amino acid sequence from the fifth to the 28th amino acid from the amino terminal, and the amino terminal
- the third amino acid residue is a peptide selected from the group consisting of peptides which are modified amino acid residues in which a fatty acid is introduced into the side chain of the amino acid residue, or a pharmaceutically acceptable salt thereof (above) 11) The method described.
- the substance has the amino acid sequence set forth in SEQ ID NO: 1, and the serine residue located third from the amino terminal is a modified amino acid residue in which a fatty acid is introduced into the hydroxyl group of the side chain of the residue.
- the substance has the amino acid sequence of SEQ ID NO: 1, and the serine residue located third from the amino terminal is a modified amino acid residue in which a fatty acid is introduced into the hydroxyl group of the side chain of the residue.
- a method for promoting skin regeneration comprising administering to a mammal in need of promoting skin regeneration, a substance that acts on a growth hormone secretion promoting factor receptor or a pharmaceutically acceptable salt thereof as an active ingredient.
- the substance has the amino acid sequence shown in SEQ ID NO: 1, and the serine residue located third from the amino terminal is a modified amino acid residue in which a fatty acid is introduced into the hydroxyl group of the side chain of the residue.
- the method according to (22) above which is a peptide.
- the above substance, wherein the substance has the amino acid sequence set forth in SEQ ID NO: 1 and the side chain hydroxyl group of the serine residue located third from the amino terminal is acylated with an n-otatanyl group (23) The method described.
- the amino acid sequence of SEQ ID NO: 1 has an amino acid sequence in which one to several amino acids are deleted, substituted and Z or appended in the amino acid sequence from the fifth to the 28th amino acid from the amino terminal, and the amino terminal
- the third amino acid residue is a peptide selected from the group consisting of peptides which are modified amino acid residues in which a fatty acid is introduced into the side chain of the amino acid residue, or a pharmaceutically acceptable salt thereof (above) 26) Use as described.
- the substance is a modified amino acid residue having the amino acid sequence set forth in SEQ ID NO: 1, wherein the serine residue located third from the amino terminal is a fatty acid introduced into the hydroxyl group of the side chain of the residue.
- (31) Use of a substance that acts on a growth hormone secretion promoting factor receptor or a pharmaceutically acceptable salt thereof as an active ingredient for producing a pharmaceutical composition for promoting skin regeneration.
- (32) A peptide in which the substance has the amino acid sequence set forth in SEQ ID NO: 1 and the third amino acid residue from the amino terminal is a modified amino acid residue in which a fatty acid is introduced into the side chain of the amino acid residue 1 to several amino acids in the amino acid sequence from the amino terminal to the 5th to 28th amino acids in the amino acid sequence shown in SEQ ID NO: 1, deletion, substitution and Z or attachment Peptides selected from the group consisting of peptides having a carotened amino acid sequence, wherein the third amino acid residue from the amino terminal is a modified amino acid residue in which a fatty acid is introduced into the side chain of the amino acid residue, or a pharmaceutical thereof Use according to (31) above, which is a chemically acceptable salt.
- the substance has the amino acid sequence set forth in SEQ ID NO: 1, and the serine residue located third from the amino terminal is a modified amino acid residue in which a fatty acid is introduced into the hydroxyl group of the side chain of the residue.
- a substance that acts on a growth hormone secretion promoting factor receptor has an action of proliferating skin cells, and a substance that acts on a growth hormone secretion promoting factor receptor when culturing the skin cells. It is possible to promptly use for treatment by adding to the cell to promote cell growth.
- skin cells are cultured to produce sheet-like artificial skin, and skin repair treatment is performed by covering the skin damage surface, artificial skin sheets are supplied to patients more quickly using cultured skin cells. It becomes possible to do.
- FIG. 1 is a diagram showing expression of GHS-Rla mRNA in fetal skin cells.
- FIG. 2 is a graph showing the effect of darrelin on intracellular calcium elevation in cultured single fetal skin cells.
- FIG. 3 is a diagram showing the action of darringin to promote the uptake of [] thymidine into fetal skin cells.
- FIG. 4 is a diagram showing the action of darling and GHRP6 to promote fetal skin cell proliferation.
- the medicament of the present invention can be used as a medicament for mammals (individuals) including humans.
- substances that can be used in the present invention include growth hormone secretion promoting factor (GHS), which is a substance (ligand) that acts on growth hormone secretion promoting factor receptor (GHS-R).
- GHS growth hormone secretion promoting factor
- known peptide compounds and low molecular weight compounds for example, ghrelin, GHRP6, MK-0677, ipamorelin, etc.
- the peptide compound darrelin is desired.
- darrelin includes human-derived darrelin and other animal-derived darrelin and its derivatives such as rats, mice, pigs, and rabbits.
- darrelin derived from an individual for each individual.
- human-derived darrelin for humans.
- Human-derived darellin consists of 28 amino acids, and is a peptide in which the side chain hydroxyl group of the third serine residue from the amino terminal is acylated with a fatty acid (n-taganol group) (SEQ ID NO: 1).
- one or several amino acids are substituted, inserted, or deleted in the amino acid residues 5 to 28 from the amino terminal in the amino acid sequence described in SEQ ID NO: 1.
- Any peptide having an amino acid sequence and having an activity of increasing intracellular calcium ion concentration by binding to a growth hormone secretagogue receptor can be used.
- the amino acid sequence of the derivative is desired to have 70%, preferably 80%, more preferably 90%, particularly preferably 95%, most preferably 97% homology compared to the natural amino acid sequence. .
- Darrelin and its derivatives according to the present invention can be obtained by conventional methods. For example, it can be isolated from natural raw materials or can be produced by recombinant DNA technology and Z or chemical synthesis. Furthermore, when an amino acid residue needs to be modified (acylation), a modification reaction can be performed according to known means. For example, in a production method using recombinant DNA technology, a host cell transformed with an expression vector having DNA encoding the peptide of the present invention is cultured, and the target peptide is collected from the culture. By doing so, darrelin and a derivative thereof according to the present invention can be obtained. The host details By selecting a cell, a compound in which the target peptide is modified (acylated) in the cell can be obtained. Further, when the peptide is not modified (acylated), a modification reaction such as acylation can be performed according to known means if desired.
- Examples of vectors into which genes are incorporated include E. coli vectors (pBR322, pUC18, pUC19, etc.), Bacillus subtilis vectors (pUB110, pTP5, pC194, etc.), yeast vectors (YEp type, YRp type, Yip type), Alternatively, any other force such as animal cell vectors (retrovirus, vaccinia virus, etc.) may be used as long as the target gene can be stably maintained in the host cell. it can.
- the vector is introduced into a suitable host cell.
- the method described in Molecular Cloning (Sambrook et al., 1989) can be used as a method for incorporating a target gene into a plasmid or a method for introducing it into a host cell.
- a promoter is connected upstream of the gene so as to function.
- the promoter used in the present invention may be any promoter as long as it is suitable for the host cell used for expression of the target gene.
- lac promoter, trp promoter, lpp promoter, ⁇ PL promoter, recA promoter, etc. can be used when the host cell to be transformed is of the genus Escherichia, and SPOl promoter, SP02 promoter, etc. if it is of the genus Bacillus.
- yeast GAP promoter, PH05 promoter, ADH promoter, etc.
- SV40-derived promoter, retrovirus-derived promoter, etc. can be used. .
- a host cell is transformed using the vector containing the gene of interest obtained as described above.
- Host cells include bacteria (eg, Escherichia genus, Bacillus genus, etc.), yeast (Saccharomyces genus, Pichia genus, Candida genus, etc.), animal cells ( CHO cells, COS cells, etc.) can be used.
- a liquid medium is suitable as a medium for culturing, and it is particularly preferable that the medium contains a carbon source, a nitrogen source, and the like necessary for the growth of the transformed cells to be cultured. Vitamins, growth promoting factors, serum, etc. can be added as desired.
- the host cell In order to directly produce a fatty acid-modified (acylated) peptide, the host cell has a processing / protease activity capable of cleaving a precursor polypeptide of the peptide at an appropriate position. It is desirable to use cells having an activity capable of acylating serine residues. A host cell having such processing protease activity and serine acylating activity transforms the host cell with an expression vector containing cDNA encoding the precursor polypeptide, and the transformed cell has calcium-elevating activity or growth hormone. It is possible to select from confirming that the production of a fatty acid-modified peptide having secretion-promoting activity.
- the peptide according to the present invention is separated and purified from the culture by a conventional method.
- a protein denaturant eg, guanidine hydrochloride
- the bacterial cells or cells are collected after culturing, suspended in a buffer solution containing a protein denaturant (eg, guanidine hydrochloride), and subjected to ultrasound. After crushing the cells or cells, centrifuge.
- gel filtration, ultrafiltration, dialysis, SDS-PAGE various chromatographies are performed in consideration of the molecular weight, solubility, charge (isoelectric point), affinity, etc. of the target substance. Separation and purification methods such as chromatography can be appropriately combined.
- GHS-Rla for example, darrelin
- its derivatives can be chemically synthesized by a conventional method.
- condensing amino acids with protecting groups by liquid phase method and Z or solid phase method, extending the peptide chain, removing all protecting groups with acid, and purifying the resulting crude product by the above purification method can be obtained.
- the side chain of an amino acid at the target position can be selectively acylated with an acylating enzyme or a acyltransferase.
- peptides according to the present invention can be easily produced according to known methods, for example, according to classical peptide synthesis methods. However, it can be easily produced according to a solid phase method.
- a fragment containing a modified amino acid residue that can be produced using a method that combines recombinant DNA technology and chemical synthesis is produced by chemical synthesis, and other fragments that do not contain a modified amino acid residue are assembled. It can also be produced by a method using recombinant DNA technology and then fusing each fragment (see International Publication WO01 / 07475).
- a pharmaceutically acceptable salt is preferable.
- the salt with an inorganic base include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; and aluminum salt and ammonium salt. Is mentioned.
- Preferable examples of the salt with an organic base include, for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexamine, ⁇ , ⁇ '-di And salts with benzylethylenediamine and the like.
- salt with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
- salts with organic acids include formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, succinic acid, succinic acid, malic acid, methanesulfonic acid, and benzenesulfonic acid. And salts with ⁇ -toluenesulfonic acid and the like.
- salts with basic amino acids include salts with arginine, lysine, ornithine and the like, and preferable examples of salts with acidic amino acids include aspartic acid, glutamic acid and the like. And the salt.
- GHS-Rla receptor which is GHS-R
- a known method can be used to measure intracellular calcium ion concentration.
- FLIPR Fluorometric Imaging Plate Reader, Molecular, which utilizes changes in fluorescence intensity of Fluo-4 AM (Molecular Probe) due to changes in calcium ion concentration. De vices
- FLIPR Fluorometric Imaging Plate Reader
- Fluo-4 AM Fluo-4 AM
- a known method can be used to confirm whether the peptide has a calcium-elevating activity and has growth hormone secretion promoting factor activity in vitro and in vivo.
- the growth hormone secreted into the cell culture medium can be measured by radioimmunoassay using an anti-growth hormone antibody.
- the concentration of growth hormone in the serum after injecting a peptide having calcium-elevating activity into the peripheral vein of the animal may be measured.
- J. Med. Chem., 43, pp. 4370-4376, 20000 can be referred to for the darrelin derivative and the preparation method thereof.
- GHS-Rla The substance acting on GHS-Rla according to the present invention (for example, darelin) has been found to have a skin cell proliferating action, as specifically shown in the examples of the present specification, The number of skin cells can be significantly increased.
- the substance acting on GHS-Rla according to the present invention is an agent for promoting skin regeneration in the treatment of skin damage (for example, wounds, abrasions, burns, etc.), skin cells (for example, epidermis, Accelerator for the formation of cultured skin cell sheets by culturing (dermis and skin), as well as burns, refractory skin ulcers, congenital epidermolysis bullosa, pressure ulcers, obesity scars, nevi, severe allergic skin diseases and hair loss etc. It can be used as an active ingredient in an agent for promoting and repairing skin repair during transplantation of cultured skin.
- skin damage for example, wounds, abrasions, burns, etc.
- skin cells for example, epidermis, Accelerator for the formation of cultured skin cell sheets by culturing (dermis and skin), as well as burns, refractory skin ulcers, congenital epidermolysis bullosa, pressure ulcers, obesity scars, nevi, severe
- GHS-Rla a substance that acts on GHS-Rla according to the present invention
- a method for treating skin damage for example, wounds, scratches, burns, etc.
- skin cells for example, Epidermis, dermis and skin
- methods for promoting the formation of cultured skin cell sheets as well as severe burns, refractory skin ulcers, congenital epidermolysis bullosa, pressure sores, obesity scars, nevi, allergic skin diseases
- it can be used in a method for promoting skin repair at the time of transplantation of cultured skin in hair loss and the like, and a method for treating the above diseases by promoting the repair.
- a substance that acts on GHS-Rla according to the present invention is used as a skin regeneration accelerator, skin cell (for example, epidermis, skin wound (for example, wound, abrasion, burn, etc.)).
- skin cell for example, epidermis, skin wound (for example, wound, abrasion, burn, etc.
- the agent of the present invention containing a substance that acts on GHS-Rla (for example, darelin) or a pharmacologically acceptable salt thereof as an active ingredient is a pharmacologically acceptable carrier or excipient. It can be used for individuals (eg, humans, mice, rats, rabbits, dogs, cats, rabbits, horses, pigs, monkeys, etc.) mixed with a bulking agent.
- the drug of the present invention is administered to an individual undergoing skin regeneration treatment parenterally, for example, by intravenous, subcutaneous, or intramuscular injection in a single dose or divided into multiple doses.
- nasal administration, pulmonary administration, and suppository administration are desirable when the individual is a human adult and is especially at home.
- the dose of the drug is not particularly limited, and can be appropriately selected according to the purpose of use and the age, weight, individual type, symptom, nutritional status, concomitant drug, etc. of the individual to be administered.
- a substance that acts on GHS—Rla eg, ghrelin
- LOOmg range power S preferably 0.01 mg to 1 Omg is more desirable!
- the above dose is preferably administered once to several times a day for 1 to 24 weeks, more preferably 1 to 12 weeks!
- the pharmaceutically acceptable carrier various organic or inorganic carrier substances commonly used as pharmaceutical materials are used. Excipients, lubricants, binders, disintegrants in solid preparations; solvents in liquid preparations , Solubilizers, suspending agents, isotonic agents, buffers, soothing agents, and the like.
- preparation additives such as preservatives, antioxidants, coloring agents, and sweeteners can be used.
- Preferable examples of the excipient include lactose, sucrose, D-manntol, starch, crystalline cellulose, light anhydrous key acid and the like.
- Preferable examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- binder Preferable examples include crystalline cellulose, sucrose, D-manntol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and the like.
- disintegrant Preferable examples include starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, croscarmellose sodium, carboxymethyl starch sodium and the like.
- Preferable examples of the solvent include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil and the like.
- solubilizer examples include polyethylene glycol, propylene glycol, D-manntol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate. And sodium quenate.
- the suspending agent include interfaces such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate.
- Activating agents for example, hydrophilic polymers such as polyvinyl alcohol, polybutylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylenoresenorelose, hydroxyethinoresenorelose, hydroxypropinoresenorelose and the like.
- Preferable examples of the isotonic agent include sodium chloride salt, glycerin, D-mannthol and the like.
- buffering agent examples include buffer solutions such as phosphate, acetate, carbonate, kenate and the like.
- the soothing agent include benzyl alcohol.
- Preferable examples of the preservative include, for example, paraoxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- antioxidant examples include sulfite, ascorbic acid and the like.
- the pharmaceutical dosage form of the invention is preferably a dosage form suitable for parenteral administration.
- the pharmaceutical dosage form suitable for parenteral administration is, for example, for intravenous administration, intradermal administration, subcutaneous administration, or intramuscular administration. Injections, infusions, suppositories, transdermal absorption agents, transmucosal absorption agents, inhalants, etc.
- preparation forms such as transmucosal absorbent, inhalant, suppository and the like are also preferable.
- These formulation forms are variously known to those skilled in the art, and those skilled in the art appropriately select a formulation form suitable for the desired administration route, and if necessary, one or more formulation additives available in the art. Can be used to produce a preparation in the form of a pharmaceutical composition.
- a medicine in the form of an injection or a drip infusion is an appropriate buffer solution, sugar solution, isotonic agent, pH regulator, together with a substance that acts on the active ingredient GHS-Rla (for example, darelin),
- GHS-Rla for example, darelin
- Addents include sugars such as glucose, mannitol, xylitol, and ratatose, hydrophilic polymers such as polyethylene glycol, alcohols such as glycerol, amino acids such as glycine, and proteins such as serum albumin.
- Salts such as NaCl and sodium quenate, acids such as acetic acid, tartaric acid and ascorbic acid, surfactants such as Tween 80, and reducing agents such as sodium sulfite can be used.
- Such a preparation can be used as an injection or an infusion by dissolving by adding distilled water for injection or physiological saline at the time of use.
- intranasal administration agents such as nasal drops and intranasal sprays are suitable, and inhalation agents are also suitable for transpulmonary administration.
- the content of the active ingredient (eg, darrelin) in a single unit preparation is 0.OOlmg to: LOOmg, preferably 0. Olmg to: LOmg, and it is desirable to administer once or several times a day.
- a substance that acts on GHS-Rla prepared by incubating the isolated skin cells in a culture solution and aseptically filtering or autoclaving in an incubation solution can be carried out by adding 0.1 ⁇ to 1 ⁇ , preferably 1 ⁇ to 10 ⁇ . That is, it is preferable to use a culture solution containing 0.000000001 mgZmL to 0.1 mgZmL of a substance that acts on GHS-Rla for the growth of skin cells. By performing this treatment, as shown in Example 4, it is possible to promote the proliferation of skin cells that hardly grow.
- GHS-Rla mRNA was expressed in the skin of rat fetuses on gestation days 14, 15, and 19.
- the expression level of GHS-Rla mRNA was high in fetal skin on days 14 and 15.
- Wistar rats on the 17th day of pregnancy were laparotomized under anesthesia and the fetuses were removed.
- a small piece of skin is collected from the fetus and treated with collagenase, papain digested and pipetted in a cold nontas solution.
- a dispersion of fetal skin cells was obtained by mechanical separation by ting. From this dispersion, single cells were obtained and calcium imaging was performed when darrelin was added. Calcium imaging was performed using a calcium imaging device (IMACS, Hamamatsu Photonicus). That is, when excited at 340nmZ380nm, the ratio of excitation light at 510nm (Emission) was taken. Fura-2 was used as a calcium imaging agent.
- IMACS calcium imaging device
- Fura-2 was used as a calcium imaging agent.
- darellin rat-derived darrelin (SEQ ID NO: 3) was used (same in the following examples).
- FIG. 2 I, ⁇ , and III are powers taken at this time. Photos are omitted in this specification.
- the solid line represents cells that responded to darrelin, and the broken line represents other cells that responded to desacyldarelin. Darrelin and desacyl ghrelin were added to separate cells.
- rat fetal skin cell dispersion was collected from Wistar rats on the 17th day of pregnancy.
- the dispersed cells were treated with MCDB153 HAA medium (F-Peptide Co., Ltd) containing 2% urine fetal serum, penicillin (lOOUZml), streptomycin (100 ⁇ g / ml), and epidermal growth factor EGF (5 ng / ml). , Yamagata, Japan) and seeded 5 ⁇ 10 5 cells Zwell in a 48-well multiwell plate covered with polyethyleneimine.
- Example 4 Cell growth-promoting action of darrelin and GHRP6 in cultured fetal skin cells
- ghrelin 0.05-500 pmolZmL (nM) or GHRP6 (0.05-50 pmolZmL (nM)
- 2% urinary fetal serum penicillin (lOOUZml)
- streptomycin 100 ⁇ g / ml
- MC DB153HAA medium F-Peptide Co., Ltd., Yamagata, Japan
- epidermal growth factor EGF 5 ng / ml
- 4- cell Z-well was inoculated with medium without darrelin or GHRP6, to which 5-bromo-2'-deoxyuridine (BrdU) (10 / z M) was added and incubated for 24 hours
- PrdU 5-bromo-2'-deoxyuridine
- Figure 4 confirms that darrelin and GHRP6 have the effect of proliferating fetal skin cells because the amount of Brd U incorporation significantly increased when darrelin or GHRP6 was allowed to act on cultured fetal skin cells. .
- the therapeutic agent for skin damage, the agent for promoting skin regeneration, the method for promoting the proliferation of cultured skin cells, and the method for promoting skin regeneration can be used in the pharmaceutical field and the medical field.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002630006A CA2630006A1 (en) | 2005-11-21 | 2006-11-21 | Skin repair accelerating therapeutic agent containing ghrelin and derivatives thereof or substance acting on ghs-r1a as active ingredient |
US12/085,221 US20090181888A1 (en) | 2005-11-21 | 2006-11-21 | Skin Repair Accelerating Therapeutic Agent Containing Ghrelin and Derivatives Thereof or Substance Acting On GHS-R1a as Active Ingredient |
EP06833072A EP1967208A4 (en) | 2005-11-21 | 2006-11-21 | THERAPEUTIC AGENT FOR SKIN OR AGENT PROMOTING REGENERATION OF SKIN CONTAINING GHRELINE, AND DERIVATIVES THEREOF OR SUBSTANCE CAPABLE OF ACTING AS ACTIVE INGREDIENT ON GHS-R1a |
JP2007545341A JPWO2007058359A1 (ja) | 2005-11-21 | 2006-11-21 | グレリン及びその誘導体又はGHS−R1aに作用する物質を有効成分とする皮膚修復促進治療剤 |
AU2006316100A AU2006316100B2 (en) | 2005-11-21 | 2006-11-21 | Therapeutic agent for skin or skin repair-promoting agent comprising ghrelin, derivative thereof or substance capable of acting on GHS-R1a as active ingredient |
BRPI0618824-9A BRPI0618824A2 (pt) | 2005-11-21 | 2006-11-21 | agente terapêutico acelerador de recuperação dérmica contendo grelina e derivados desta ou substáncias que atuam sobre ghs-r1a como ingrediente ativo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-336418 | 2005-11-21 | ||
JP2005336418 | 2005-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007058359A1 true WO2007058359A1 (ja) | 2007-05-24 |
Family
ID=38048737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/323226 WO2007058359A1 (ja) | 2005-11-21 | 2006-11-21 | グレリン及びその誘導体又はGHS-R1aに作用する物質を有効成分とする皮膚修復促進治療剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090181888A1 (ja) |
EP (1) | EP1967208A4 (ja) |
JP (1) | JPWO2007058359A1 (ja) |
KR (1) | KR20080075530A (ja) |
CN (1) | CN101312745A (ja) |
AU (1) | AU2006316100B2 (ja) |
BR (1) | BRPI0618824A2 (ja) |
CA (1) | CA2630006A1 (ja) |
RU (1) | RU2420306C2 (ja) |
WO (1) | WO2007058359A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009142307A1 (ja) * | 2008-05-23 | 2009-11-26 | アスビオファーマ株式会社 | 目的ペプチドの血漿中半減期延長作用を有するペプチド |
JP2018513148A (ja) * | 2015-04-10 | 2018-05-24 | アイエスピー・インヴェストメンツ・リミテッド・ライアビリティ・カンパニー | 細胞老化および皮膚加齢徴候の出現を低減または遅延させるための配列His−D−Trp−Ala−Trp−D−Phe−Lys−NH2を有するペプチドの新規な使用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080082651A (ko) * | 2005-11-21 | 2008-09-11 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | 데스아실 그렐린 및 그 유도체를 유효 성분으로 하는 피부수복 촉진 치료제 |
KR101667383B1 (ko) | 2012-03-28 | 2016-10-18 | 주식회사 인코스팜 | 비오틴이 결합된 hexapeptide-2 유도체 및 이의 용도 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004000251A (ja) * | 1999-07-23 | 2004-01-08 | Kenji Sagawa | 新規ペプチド |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
CN100411683C (zh) * | 2002-05-21 | 2008-08-20 | 阿斯比奥制药株式会社 | 含有生长素释放肽的药物组合物 |
-
2006
- 2006-11-21 EP EP06833072A patent/EP1967208A4/en not_active Withdrawn
- 2006-11-21 KR KR1020087014850A patent/KR20080075530A/ko not_active Application Discontinuation
- 2006-11-21 US US12/085,221 patent/US20090181888A1/en not_active Abandoned
- 2006-11-21 WO PCT/JP2006/323226 patent/WO2007058359A1/ja active Application Filing
- 2006-11-21 AU AU2006316100A patent/AU2006316100B2/en not_active Expired - Fee Related
- 2006-11-21 JP JP2007545341A patent/JPWO2007058359A1/ja active Pending
- 2006-11-21 RU RU2008125169/15A patent/RU2420306C2/ru not_active IP Right Cessation
- 2006-11-21 BR BRPI0618824-9A patent/BRPI0618824A2/pt not_active IP Right Cessation
- 2006-11-21 CA CA002630006A patent/CA2630006A1/en not_active Abandoned
- 2006-11-21 CN CNA2006800434502A patent/CN101312745A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004000251A (ja) * | 1999-07-23 | 2004-01-08 | Kenji Sagawa | 新規ペプチド |
Non-Patent Citations (3)
Title |
---|
GEELISSEN S.M.E. ET AL.: "Distribution and regulation of chicken growth hormone secretagogue receptor isoforms", GENERAL AND COMPARATIVE ENDOCRINOLOGY, vol. 134, no. 2, 2003, pages 167 - 174, XP003009099 * |
NAKAHARA K. ET AL.: "Maternal ghrelin plays an important role in rat fetal development during pregnancy", ENDOCRINOLOGY, vol. 147, no. 3, 2006, pages 1333 - 1342, XP003009100 * |
See also references of EP1967208A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009142307A1 (ja) * | 2008-05-23 | 2009-11-26 | アスビオファーマ株式会社 | 目的ペプチドの血漿中半減期延長作用を有するペプチド |
JP5524049B2 (ja) * | 2008-05-23 | 2014-06-18 | 第一三共株式会社 | 目的ペプチドの血漿中半減期延長作用を有するペプチド |
JP2018513148A (ja) * | 2015-04-10 | 2018-05-24 | アイエスピー・インヴェストメンツ・リミテッド・ライアビリティ・カンパニー | 細胞老化および皮膚加齢徴候の出現を低減または遅延させるための配列His−D−Trp−Ala−Trp−D−Phe−Lys−NH2を有するペプチドの新規な使用 |
Also Published As
Publication number | Publication date |
---|---|
RU2008125169A (ru) | 2009-12-27 |
US20090181888A1 (en) | 2009-07-16 |
EP1967208A1 (en) | 2008-09-10 |
RU2420306C2 (ru) | 2011-06-10 |
KR20080075530A (ko) | 2008-08-18 |
BRPI0618824A2 (pt) | 2011-09-13 |
EP1967208A4 (en) | 2009-09-02 |
AU2006316100B2 (en) | 2011-12-01 |
CA2630006A1 (en) | 2007-05-24 |
JPWO2007058359A1 (ja) | 2009-05-07 |
AU2006316100A1 (en) | 2007-05-24 |
CN101312745A (zh) | 2008-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11795204B2 (en) | Glucagon analogues | |
KR102092025B1 (ko) | 페길화된 옥신토모둘린 변이체 | |
EP2051995B1 (en) | Selective glucagon-like-peptide-2 (glp-2) analogues | |
RU2498814C2 (ru) | Пэг-модифицированный эксендин или аналог эксендина и его композиции и применение | |
US7595294B2 (en) | Vasoactive intestinal polypeptide pharmaceuticals | |
JP2010155859A (ja) | 生物活性ケラチンタンパク質 | |
KR20070067136A (ko) | 혈관작용성 장내 폴리펩티드 제약 | |
US10166295B2 (en) | Pegylated OXM variants | |
WO2007058359A1 (ja) | グレリン及びその誘導体又はGHS-R1aに作用する物質を有効成分とする皮膚修復促進治療剤 | |
AU2016273045B2 (en) | Pegylated oxyntomodulin variants | |
US8940868B2 (en) | Elastin based growth factor delivery platform for wound healing and regeneration | |
WO2007058360A1 (ja) | デスアシルグレリン及びその誘導体を有効成分とする皮膚修復促進治療剤 | |
KR20090060291A (ko) | 그렐린 및 그 유도체 또는 GHS―R1a에 작용하는 물질을 유효성분으로 포함하는 척수 신경 수복 촉진 치료제 | |
JPWO2008018597A1 (ja) | デスアシルグレリン及びその誘導体を有効成分とする脊髄神経修復促進治療剤 | |
US20230012823A1 (en) | GhR-BINDING PEPTIDE AND COMPOSITION COMPRISING SAME | |
CN1557954A (zh) | 转导肽-人胰岛素原融合蛋白的表达与应用 | |
CN112500493A (zh) | 重组人神经调节蛋白衍生物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680043450.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006316100 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 191239 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007545341 Country of ref document: JP Ref document number: 1927/KOLNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2630006 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006316100 Country of ref document: AU Date of ref document: 20061121 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006833072 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087014850 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008125169 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12085221 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0618824 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080520 |